Background: Instigating a patient support group for patients with pernicious anaemia (PA) revealed dissatisfaction with its current diagnosis and treatment. The authors investigated the clinical features, patient experience of diagnosis and treatment of PA in the UK. Methods: A total of 889 patients registered with the PA Society support group completed an online survey or postal questionnaire. Outcome measures included clinical features, length of time to diagnosis and patient satisfaction with current treatment Results: One-third of patients experienced symptoms for up to 1 year before diagnosis; 14% waited more than 10 years for a diagnosis. Neurological features were highly prevalent, the most common being memory loss and poor concentration. Nearly two-thirds of respondents were dissatisfied with current treatment; 10% used a non-licensed form of B12 to supplement their prescribed injections. Conclusion: The diagnosis and treatment of PA should be subject to a thorough review. This article discusses the patient survey and results and makes recommendations for how the diagnosis and treatment of PA may be evaluated.
A fatal form of anaemia associated with stomach degeneration was first described in 1824 by JS Combe in Edinburgh and later by Thomas Addison, a physician at Guy's Hospital in 1849 (Combe,1824; Pearce,2004) .Biermer(1872)coinedtheterm perniciousanaemia(PA)basedontheinevitablyfataloutcome ofthedisorder.PApreventsthebodyfromabsorbingvitamin B12,whichisofcourseessentialforlife.
This disease remained incurable until 1926 when two American physicians, Minot and Murphy, described a raw liver diet that cured PA (Minot and Murphy, 1926) . Liver extractsweremadewhichreversedPAindogsandhumans. Forthenexttwo decades,liverwasthemainsourceofthis unknowncuringfactorcalled'extrinsicfactor'. Castle(1929) Martyn Hooper, Peter Hudson, Fiona Porter and Andrew McCaddon observed that gastric juice contained a protein he called 'intrinsicfactor',whichfurtherenhancedthecurativeeffects oftheextrinsicfactor.
In 1948, two independent teams in the USA (Rickes et al, 1948) and England (Smith and Parker, 1948) isolated the mysterious extrinsic factor as a pure crystal. Folkers calledit'vitaminB12.'DorothyHodgkin,aBritishchemist, elucidated the unique and complex chemical structure of this large molecule using X-Ray crystallography (Hodgkin etal,1955) (Figure 1 ).ShewasawardedtheNobelPrizefor chemistry in 1964 for this monumental achievement.The productionofvitaminB12onanindustrialscaleintheearly fiftiesenableditsworldwidemedicalapplicationtotreatPA.
Total human body content of vitamin B12 is 2-5 mg. Dailylossesareestimatedtobeabout0.1-0.2%ofthetotal content and correspond equally to urinary and digestive excretion.Anormaldietprovides5-15 μgofvitaminB12per daybut60-80%ofingestedvitaminiseliminatedinstoolsor metabolisedbyintestinalflora.Requirementsvarydepending onage.Therecommendeddailydietaryamountsforadults, pregnant women, and infants are set at 3.0, 4.0, and 0.5 μg respectively (GreenandMiller,2007) .
Vitamin B12 occurs solely in food of animal or bacterial origin. Examples of foods high in B12 include shellfish (cooked clams 98.9 μg/100 g); liver (83.1 μg/100 g); fish (mackerel19 μg/100 g);redmeat(beef6 μg/100 g);cheese (swiss 3.3 μg/100 g); eggs (yolks 2 μg/100 g; typical whole egg0.36 μg);andskimmedmilk(0.5 μg/100 g).Somefoods arefortifiedwithvitamin B12,andcanbeusedasalternative sources, e.g. cereal ('All Bran' 20 μg/100 g); soy products ('SilkenTofu' 2.4 μg/100 g) and yeast extracts ('Marmite' 0.5 μg/100 g).The vitamin B12 in these foods is mainly intheformofmethyl-B12andadenosyl-B12.Food B12is alwaysprotein-boundandreleasedbythesequentialprocesses ofcookingandacid-dependentpepticdigestion.
Absorbtion of vitamin B12
To understand why vitamin B12 deficiency occurs, it is necessary to know how it is normally absorbed from food. Fromthepointofentryatthemouth,foodisacteduponby aseriesofenzymesbeforethevitaminisfinallyreleasedinto thebloodstream.
Saliva is a major source of cobalophilin (CP)-the first proteintobindB12initsassimilation.Inthestomach,gastric chymeandpepsinreleaseB12fromdietaryproteinenabling it to bind to CP. Gastric parietal cells are the source of a secondB12-bindingprotein,intrinsicfactor(IF)mentioned above.Inthealkalineconditionsoftheduodenum,thisbinds ©2014MAHealthcareLtd strongly to the small amounts of B12 released from food anddegradedCP-B12.ThesubsequentIF-B12complexis resistant to further digestion; it binds to a specific receptor in the terminal ileum. Bile is also important for the body's regulation of B12. There is an entero-hepatic circulation of the vitamin that perhaps helps eliminate its potentially harmfulanalogues (elKholtyetal,1991) .Corrinoids(active B12anditsinactiveanalogues)areexcretedinbileboundto CP.PartialdegradationofCPbypancreaticenzymesreleases active B12 that binds to IF and is re-absorbed, whereas inactiveanaloguesareexcreted.
There are two mechanisms for B12 absorption in the ileum: passive diffusion and uptake via a specific IF-B12 complex receptor. B12 is rapidly internalised in enterocytes whereitistransformedintomethyl-B12inthecytosoland adenosyl-B12 in the mitochondria. These then attach to a third binding protein, transcobalamin (TC), and 3 hours afterabsorption,thevitaministransportedintothebloodas holo-TC.
Following binding of holo-TC to the TC receptor on cells, B12 is retained and converted to its coenzyme forms (Quadrosetal,2009 ).TherearetwoB12-dependentenzymes in mammalian cells, methylmalonyl-CoA mutase (MCM) and methionine synthase. MCM catalyses the conversion of L-methylmalonyl-CoA to succinyl-CoA. This requires adenosyl-B12 as a cofactor. Methionine synthase catalyses theconversionofhomocysteinetomethionineandrequires methyl-B12asacofactor.
PA and other causes of vitamin B12 deficiency
Reduced dietary intake is an uncommon cause of B12 deficiency,occurringonlyinvegans,childrenofvegans, and in cases of severe prolonged malnutrition.Vegans make up2%oftheUKpopulation (DepartmentforEnvironment, FoodandRuralAffairs,2007) .Theprevalenceofvitamin B12 deficiency ranges from 47.8% to as high as 86.5% in strict vegans (Pawlak et al, 2014) . More commonly, the vitamin maybemalabsorbedasaresultofdisordersaffectinganypart ofthegastrointestinaltractfromthestomachtotheileum.
Intra-gastric factors
Acid and pepsin are necessary for the release of B12 from foodanditstransfertoCPinthestomach.Potentialcausesof deficiencythereforeincludenon-specificgastritis(associated with helicobacter pylori) and other gastric diseases and surgery,acid-suppressingdrugsandalcoholabuse.
Intrinsic factor deficiency
Intrinsicfactor(IF)deficiencymayresultfromanautoimmune disorder(e.g.PA),atrophicgastritisorsurgicalresection,allof whichresultindefectivesecretion.
Autoimmune PA is prevalent in Europeans, especially Scandinavians. It is frequently associated with other autoimmune diseases such as Hashimoto's thyroiditis and adrenocorticalinsufficiency.Inadditiontoanaemia,patients mayhavepathognomonicanti-IFantibodiesandantiparietal cellantibodiesinserum.
Some forms of atrophic gastritis are accompanied by B12 deficiency, and can be difficult to distinguish from PA although they are far more frequent.Total and partial gastrectomy and/or vagotomy can also result in deficiency (Roos,1978) .
Pancreatic insufficiency
B12 deficiency can also occur as a result of chronic pancreatitis, other exocrine pancreatic insufficiencies and cysticfibrosis.
Intestinal factors
There are many potential causes of B12 malabsorption relating to the intestine including ileal resection, radiation injury,ilealdiseasesuchasCrohn'sdisease,parasiticinfestation, obstructivejaundiceandcoeliacdisease.
Rare causes
Rare causes of deficiency include non-functional transport through the ileum (Imerslund Gräsbeck syndrome) and deficiency of binders (holo-TC deficiency) (Linnell and Bhatt,1995) .Thereisalsothepossibilitythatdeficiencycan resultfromexcessrequirementsorincreasedcatabolismofthe vitamin (McCaddon,2013) .
Treatment of vitamin B12 deficiency
In the UK, replacement therapy is usually given by regular intramuscular injections of hydroxocobalamin (1000 μg), bypassingtheneedforIFandallowingthevitamintoabsorb bydiffusion.About10%oftheinjecteddoseisretained.For patientswithoutneurologicalinvolvement,thisisusuallygiven threetimesaweekfor2 weeks,thenat3-monthlyintervals. For patients with neurological involvement, it should be givenonalternatedaysuntilthereisnofurtherimprovement and then at 3-monthly intervals (Royal Pharmaceutical Society, 2013) .There is some evidence that daily oral high doses of vitamin B12 (1000-2000 μg) are as effective as intramuscular injection in achieving haematological and neurologicalresponses (Butleretal,2006) .Oralreplacement is used in some countries, including Sweden and Canada. SomepatientswithPAsubsequentlydevelopirondeficiency resulting from an associated chronic atrophic gastritis. Such patientsshouldbefurtherinvestigatedwithendoscopyowing toaslightincreasedriskofgastriccarcinoma (HvasandNexo, 2006) .Someexpertsalsosuggestsurveillanceendoscopyfor gastric malignancy and carcinoid every 5 years in young patientswithPA (Borch,1986; Armbrechtetal,1990) . The PerniciousAnaemia (PA) Society was established as a patient support group in 2006. Its remit was to provide patients with a plain English explanation of their diagnosis. Itsoonbecameclearfrompostsinthesociety'sonlineforum, and later from telephone enquiries, that there were issues andconcernssurroundingthetimetakenforpatientstobe diagnosedwithPA.
Italsobecameapparentthatmanypatientswereunhappy with the treatment they were receiving. In particular, they feltdoctorsfailedtoappreciatethatmorefrequentinjections often helped their symptoms; these were usually denied on the basis of vitamin B12 levels returning to normal. More worryingly,severalpatientsreportedthatreplacement,which shouldbelifelong,wasdiscontinuedfollowingrestorationof bloodvitamin B12levels. Thesocietyrealisedthatinordertoraiseawarenessofthese problems, it would need more than anecdotal evidence no matterhowplentifulthiswas.Thisarticledescribestheresults ofasurveyofPASocietymembersintheUKcollectedover an18-monthperiod.
Methodology
AnonlinesurveywasdesignedbyaGPusingSurveyMonkey software and placed on the charity's website (http://www. surveymonkey.com/s/XMNY6R5).
Existing online members (approximately 3500) logging onto the website were given the opportunity to complete the survey but once completed, members would not be promptedtocompletethesurveyagainonsubsequentlogins.
The society's'paper members' (approximately 200) were also sent a hard copy to complete and return.All responses werecollatedinasingleelectronicdataset.Everynewonline member was offered the same opportunity as full members tocompletethesurveywhentheyfirstloggedonduringthe studyperiod.
Atotalof38 questionswereasked.Theseincluded: 
Results
BetweenAugust2010andNovember2012,1184individuals completed the questionnaire. After eliminating those who filled in the questionnaire on behalf of a friend or family member, and non-UK respondents, 889 completed questionnaires remained.All reported percentages are based onthistotalnumber.
There were 721 female and 168 male respondents.There is no direct data regarding the incidence of PA between sexesbutthemuchhigherincidenceoffemalesinthefamily historyofPAsuggestsitmaybemoreprevalentinfemales. We have to note however that this survey was taken from members of the PA society, and that females are perhaps morelikelytojoinforumsandsocietiesthanmen.Theages of respondents at the time of diagnosis of PA varied from less than 10 years (4 individuals) to greater than 80 years (12 individuals). The most frequent age at diagnosis was 41-50 years (228 individuals).The majority of respondents (850) regarded their ethnicity as 'White European'. Again, thePA Society,thoughworld-wide,isbasedintheUK,and UK residents,mostofwhomareWhiteEuropean,makeupa veryhighpercentageofitsmembership.
Of the respondents, 135 had a parent with PA. Other reported family members with the disorder included a grandparent(130),asibling(54),achild(20),anuncleoraunt (83)andacousin(33).
There were 304 individuals who experienced symptoms of the disorder for up to a year before the diagnosis of PA wasmade.Somehadtowaitup2 years(193),5 years(173), 10 years(40)ormore;127individualsexperiencedsymptoms formorethan10 yearspriortoreceivingtheirdiagnosis.
Most of the individuals (99%) reported a range of generalsymptoms,predominantlytiredness(96%)butalso(in decreasing order of frequency)'waking up tired' (87%), dry skin(58%),brittlenailswith(47%)orwithout(37%)ridging, flushes or fever (43%), glossitis (34%), hair loss or greying (30%), weight loss (21%) and jaundice (6%).The remaining 1%reportednosymptomsandtheirB12deficiencywillhave beenanincidentalfinding.
Mostindividuals(98%)alsoreportedarangeofneurological symptomsincludingmemoryloss(78%),poorconcentration (75%),clumsiness(66%),pinsandneedles(66%),poorsleep (64%), confusion (62%), dizziness (59%), headaches (52%), nominal aphasia (word-finding difficulties) (50%),'shoulder bumps'(frequentlybumpingintothingsasaresultofbalance problems) (48%), unable to stand with eyes closed (34%), Grierson syndrome (33%) and vertigo (33%). Cardiorespiratory symptoms were reported by 86% of individuals, comprisingshortnessofbreath(73%)andpalpitations(56%). Gastrointestinalproblemswerecommonlyreported(82%). Theseincludeddiarrhoea(58%),indigestion(42%),diarrhoea followingconstipation(40%),stomachcramps(39%),lossof appetite(27%)andlossoftaste(26%).
Emotionalsymptomswerealsocommonlyreported(86%), includingirritability(75%),impatience(64%),moodswings (58%) and suicidal thoughts (22%). Finally, 21% reported urinarytractinfection.
Many patients reported a co-existing diagnosis. These included depression (45%), tinnitus (34%), psoriasis, eczema or acne (28%), folic acid deficiency (23%), arrhythmia (21%), hypothyroidism (19%), vitiligo (patchy skin depigmentation) (13%), rheumatoid arthritis (8%), diabetes mellitus (6%), coeliac disease (6%), previous Helicobacter pyloriinfection(5%),psoriaticarthritis(4%),hyperthyroidism (3%), hyperparathyroidism (1%), gastrectomy (1%), multiple sclerosis(0.2%)andgastriccancer(0.1%).
Atdiagnosis,thefollowinginvestigationswereundertaken: serum B12 (67% of individuals), serum folate (34%), serum intrinsicfactorantibodies(IFA)(32%),endoscopy(15%)and serumparietalcellantibodies(PCA)(14%).
The results showed low serum B12 (51% of individuals), low serum folate (17%), positive IFA (10%), normal serum folate (9%), negative IFA (9%), positive PCA (6%), normal endoscopy result (6%), negative PCA (4%), abnormal endoscopyresult(3%)andnormalserumB12(2%). IndividualswereaskedtoreportwhichformofB12they weretaking.Atotalof56%weretakinghydroxocobalamin, 10% were taking methylcobalamin and 8% were taking cyanocobalamin. These were delivered mainly via intramuscularinjection(88%).Sublingualtablets(4%),tablets (3%), subcutaneous injection (3%) and sublingual spray, sublingualdrops,behindtheearpatchandnasalspray(all1% orless)werealsolesserusedmodesofdelivery.Therapywas usuallyadministeredatahealthclinic(83%),andbyasmaller groupofpeopleviaself-injection(6%),byafriendorfamily member(2%)orataprivateclinic(1%).
OfthoseindividualsreceivingB12byinjection,<1%were beingtreatedmorethanonceaday;1%werebeingtreated daily;2%weekly;9%monthly;15%twice-monthly,50%once every3 monthsand10%werebeingtreatedatsome'other' frequency.
When asked if they were satisfied with their treatment, 64%said'No',28%said'Yes'andtheremaining8%didnot provide an answer. Respondents were asked which word bestdescribedhowtheyratedtheirmedicalcare.Theresults were:VeryPoor(20%),Inadequate(18%),Good(10%),Poor (10%), Undecided (9%), Reasonable (8%), Adequate (8%), VeryGood(7%),Excellent(3%)andUnreasonable(2%).The remainingrespondentsdidnotanswerthequestion.
BeforethefinaldiagnosisofPAwasmade,respondentswere askediftheywereincorrectlygivenanotherexplanationfor theirsymptoms.50%said 'No',44%said 'Yes'andtheremaining 6%didnotanswer.Therespondentswereinvitedtodescribe these.The most frequent was anxiety or depression (143). The next most common were chronic fatigue syndrome/ myalgic encephalopathy (46), anaemia/iron deficiency (42), irritablebowelsyndrome(39),hypothyroidism(35),multiple sclerosis (24), hypochondria (22), fibromyalgia (21), coeliac disease (18),fatigue(14),menopause(14),diabetes(11)and post-viral(11).Therewerenumerousotherexplanationswith lessthan10 respondentsidentifyingeach.
Discussion
Recent appraisals of the clinical features and diagnostic course of PA are sparse (Hvas and Nexo, 2006; Song et al, 2013; Stabler, 2013) . The survey described in this article was prompted because PA Society members expressed dissatisfaction with their treatment and the time taken to reachadiagnosis.Thiswasconfirmedbyfindingthatnearly two-thirds of respondents were dissatisfied with current treatmentandthatone-thirdhadexperiencedsymptomsfor uptoayearbeforediagnosis.Nearly22%hadtowait2 years, 19% for 5 years and 4% for 10 years. Regrettably, 14% of individuals experienced symptoms for more than 10 years beforearrivingattheirdiagnosis.
Manysymptomsdescribedarenon-specificbutnevertheless recognisedbyhealthprofessionalsaspossiblefeaturesofPA. However, the survey also revealed a high prevalence of less typical features that should alert health professionals to the possibility of B12 deficiency. It also provided additional insight into otherwise 'textbook' features. For example, tirednesswasanalmostuniversalsymptom,butdescribedas 'wakinguptired,'anda'strangetiredness'despiteanadequate period of sleep. Other features not typically associated with PAincludefrequentreportsofbrittlenails,flushing,fever,hair lossandgreying.
Patients had a markedly high prevalence of neurological features, the most common being memory loss and poor concentration. This is consistent with the increasingly recognisedimportanceofthevitamininrelationtocognitive declineandincidentdementia (Groberetal,2013; McCaddon, 2013) . In a recent study of metabolic B-vitamin deficiency in patients with mild cognitive impairment, the beneficial effects of three B vitamins in slowing brain shrinkage were predominantly mediated by vitamin B12 (Douaud et al, 2013) .Itisimportantforhealthprofessionalstobeawarethat theneurologicalandhaematologicalfeaturesofvitamin B12 deficiency are frequently dissociated (Lindenbaum et al, 1988) . In addition to typical neurological features such as paraesthesia(pinsandneedles),halfofpatientsalsoreported word-findingdifficulties.Nominalaphasiaisnotarecognised feature of PA but has been reported in association with metabolicB12deficiency (McCrackenetal,2006) .
Gastrointestinal features including diarrhoea were also extremely common, as were emotional symptoms such as irritabilityandmoodswings.Interestingly,thereisincreased awarenessofanassociationbetweenvitamin B12deficiency and depressive symptomatology, particularly in the elderly (Tiemeieretal,2002; Lachneretal,2012) .
Surprisingly, one third of individuals reported not having had a B12 assay at the time of diagnosis. Similarly, only one-third reported having had anti-IF antibodies measured. However, patients were instructed to leave these questions unanswered if they were unsure. Most patients received intramuscular injections at a health clinic. Of these, half reportedaninjectionatafrequencyofevery3 months.
The majority of patients were dissatisfied with their OnepotentialsourceofbiasisthatdissatisfiedPA patients are perhaps more likely to register with a patient support group.Anotherdifficultyofinterpretationiswhetherpatients completing the questionnaire 'genuinely' had PA; they may incorrectly believe that the condition is synonymous with B12 deficiency which, in addition to the causes listed previously, can also arise from recreational use of nitrous oxide(whippits)andseveralprescriptionmedicinesincluding metformin,colchicineandprotonpumpinhibitors.
Nevertheless,whatevertheunderlyingcause,itisclearthat therecognitionofvitamin B12deficiencyanditstreatment are considered sub-optimal by most patients. Treatment dissatisfaction presumably arises from individual variability inclinicalresponsetovitamin-B12replacement.Thereasons forthisareunknown.Itmightreflectanoverlyprescriptive approach to treatment coupled with genetic determinants of B12-tissue delivery such as polymorphisms of the B12-transport protein (TC), and/or its receptor (McCaddon, 2013) .Theauthorsarenotawareofanyothersurveysshowing theconsiderablelengthoftimetakentoreachadiagnosisof PA,andhealthprofessionalsarelikelytobeunawareofthis. Thisstudyisimportantinhighlightingthecurrentsituation.
The role of the nurse
Thesurveyrevealedconsiderablepatientdissatisfactionwith treatment.Theroleofthenurseisvitalinthemanagement of B12-deficient patients. As the health professional likely to have the most ongoing contact with the patient, nurses are best suited to re-evaluate patient symptoms and discuss optimaldosingwithboththepatientandphysician.
Recommendations
This large UK-based survey revealed considerable dissatisfaction among patients, suggesting that a review of the current diagnosis and treatment of PA in particular, and vitamin B12 deficiency in general, should perhaps be undertaken.
As well as validating some of the novel symptomatology presented here, such a review could further evaluate the use of newly developed tests for B12 status including breath tests (Wagner et al, 2011) and the'active B12 test' (holo-TC) (Sobczynska-Malefora et al, 2014) .The clinical role of ancillary tests of absorption (the 'CobaSorb' test) also needs clarification. In CobaSorb, the absorption of an oral dose of B12 is reflected by an increase in holo-TC in healthy individuals (Hvas et al, 2011) . So far, this has only beenevaluatedinafewpatientswithacquiredvitaminB12 deficiency,includingPA.
Itwouldalsobehelpfultoformallyevaluatethealternative delivery methods for replacement B12 therapy that have become available in recent years; these include nasal sprays, sub-lingual drops and sprays, transdermal patches, suppositoriesandself-administeredsub-cutaneousinjections ofmethyl-B12.
The survey described in this article suggests that patients are currently diagnosed late, their symptoms are poorly controlled and their satisfaction with their condition's managementispoor.
Health professionals have a responsibility for providing goodcare.TestscurrentlyusedbytheNHSforthediagnosis of PA are relatively insensitive. The only guidelines for treatmentaregivenintheBNF,andthesearebothoutdated intheirapproachandrestrictive.Withmodernadvancement inthisfield,thereislikelytobeanincreaseinthenumberof patientsdiagnosedwithB12 deficiency.Inaddition,ifpatients aretreatedaccordingtotheirsymptoms,injectionswillalso becomemorefrequent.
Nurses are ideally placed to act as the patient's advocate inachievingabetterstandardofcareinB12 deficiency.The symptoms experienced by these patients are often lifestylelimiting and sometimes life-limiting.The impact of better caretopatientswouldbeimmeasurable. 
BJN

Conflict of
KEY POINTS
n Pernicious anaemia prevents the body from absorbing vitamin B12 n Vitamin B12 was first identified 65 years ago n Treatment regimes for its deficiency are based on metabolic studies in the 1960s n A patient support group highlighted dissatisfaction with the current treatment and diagnosis of PA n The survey described in this article confirms this, suggesting that a review of the clinical management of B12 deficiency should be undertaken
